# US 2018/0021300 A1 · Formulation for soft anticholinergic analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021300 A1
- Document ID: US20180021300A1
- Status: Published application
- Kind: A1
- Application number: 15/656,273
- Filed: 2017-07-21
- Published: 2018-01-25
- Earliest claimed: 2016-07-21
- Assignees: Bodor Laboratories, Inc.
- Applicants: Bodor Laboratories, Inc.
- Inventors: Nicholas S. BODOR; John J. KOLENG; David ANGULO
- Web page: https://patentgrep.com/patent/US20180021300A1

## CPC

- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

## Claims

### Claim 1

A topical composition for treating, inhibiting or ameliorating excessive sweating, said composition comprising the following ingredients:
(a) a compound having the formula:
said compound having the R stereoisomeric configuration at the 2 position and the R, S or RS stereoisomeric configuration at the 1′ and 3′ positions, or being a mixture thereof;
(b) anhydrous ethanol;
(c) optionally, at least one gelling or viscosity-controlling ingredient;
(d) isopropyl myristate; and
(e) optionally, at least one additional carrier or excipient
provided that said topical composition is anhydrous and comprises from about 1% to about 25% w/w of the compound of formula (2), said composition having greater storage stability compared to a composition comprising an aqueous solvent or aqueous buffer, with the proviso that said ingredients are present in amounts such that the product of any transesterification is the same as the compound of formula (2), and/or with the proviso that said anhydrous ethanol is present in an amount sufficient to act as a non-aqueous solvent for the compound of formula (2).

### Claim 2 (depends on 1)

The composition of claim 1, comprising at least about 70% w/w anhydrous ethanol.

### Claim 3 (depends on 1)

The composition of claim 1, comprising from about 70% to about 99.99% w/w anhydrous ethanol.

### Claim 4 (depends on 1)

The composition of claim 1, comprising from about 70% to about 85% w/w anydrous ethanol.

### Claim 5 (depends on 1)

The composition of claim 1, comprising at least one gelling or viscosity-controlling ingredient.

### Claim 6 (depends on 1)

The composition of claim 1, comprising at least one additional carrier or excipient.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the compound of formula (2) is selected from the group consisting of:
(i) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;
(ii) (2R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;
(iii) (2R,3′R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;
(iv)(2R,3′S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;
(v) (2R,1′R,3′S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;
(vi)(2R,1′S,3′S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;
(vii) (2R,1′R,3′R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide; and
(viii) (2R,1'S,3′R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the compound of formula (2) is present at a concentration of from about 1% w/v or w/w to about 20% w/v or w/w of the composition.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the compound of formula (2) is present at a concentration of from about 2% w/v or w/w to about 10% w/v or w/w.

### Claim 10 (depends on 1)

A package comprising a multiple dose container, wherein the multiple dose container meters a dose of from about 0.5 ml to about 1.0 ml of the composition of claim 1 for each application.

### Claim 11 (depends on 1)

A package comprising a single or unit dose container, wherein the single or unit dose container delivers a single or unit dose of about 0.5 ml to about 1.0 ml of the composition of claim 1 for each application.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the compound of formula (2) is (2R,3′R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide.

### Claim 13 (depends on 5)

The composition of claim 5, wherein the gelling or viscosity-controlling ingredient is hydroxypropyl cellulose.

### Claim 14 (depends on 1)

The composition of claim 1, further comprising citric acid.

### Claim 15 (depends on 1)

The composition of claim 1, further comprising hexylene glycol.

### Claim 16 (depends on 1)

The composition of claim 1, further comprising at least one member selected from the group consisting of dimethicone and cyclomethicone.

### Claim 17 (depends on 1)

The composition of claim 1, further comprising a 6% silicone gum blend in dimethicone.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 1)

A method of treating hyperhidrosis in a subject, said method comprising topically administering the composition of claim 1 to skin of an area of a subject suffering from hyperhidrosis, before bedtime, such that, compared to untreated, baseline conditions, sweat production is reduced by at least 25% for at least six (6) hours; and such that sweat production is reduced by an amount substantially equivalent to an amount that sweat production is reduced as compared to untreated, baseline conditions, following administration of a composition comprising the same concentration of glycopyrrolate, and with an improved safety profile compared to topical glycopyrrolate.

### Claim 21 (depends on 1)

A method of treating hyperhidrosis in a subject, said method comprising topically administering the composition of claim 1 to skin of an area of a subject suffering from hyperhidrosis, such that, compared to untreated, baseline conditions, sweat production is reduced by at least 25% for at least six (6) hours; and such that sweat production is reduced by an amount substantially equivalent to an amount that sweat production is reduced as compared to untreated, baseline conditions, following administration of a composition comprising the same concentration of glycopyrrolate, and with an improved safety profile compared to topical glycopyrrolate.

### Claim 22 (depends on 20)

The method of claim 20, wherein said composition is topically administered in a one to four times daily regimen to an affected skin area of the subject.

### Claim 23 (depends on 20)

The method of claim 20, wherein said composition is topically administered to an affected skin area of the subject, within 1-2 hours prior to the subject's sleep period.

### Claim 24 (depends on 21)

The method of claim 21, wherein said composition is topically administered in a one to four times daily regimen to an affected skin area of the subject.
